Survodutide Side Effects: How Common, How Long They Last
Survodutide is still in trials. People lost 16.6% of their body weight on average in its main study so far.
- Average weight lost
- 16.6%
- Trial length
- 76 weeks
Survodutide in brief
In SYNCHRONIZE-1, weight loss at 76 weeks was measured as a percentage of body weight using the efficacy estimand, versus 3.2% for placebo.
Sources: boehringer-ingelheim.com.
Approved options and trial results
Survodutide can currently be prescribed only in a trial. These approved medicines can have the following results in their main weight trials:
| Trial | Dose group | Average weight lost | Placebo or comparison | Weeks | Who was in it |
|---|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg weekly | 14.9% | 2.4% | 68 | Adults with obesity or overweight, without diabetes |
| OASIS 4 | Wegovy pill 25 mg daily | 13.6% | 2.4% | 64 | Adults with obesity or overweight, without diabetes |
| SURMOUNT-1 | Tirzepatide 15 mg weekly | 20.9% | 3.1% | 72 | Adults with obesity or overweight, without diabetes |
| SURMOUNT-2 | Tirzepatide 15 mg weekly | 14.7% | 3.2% | 72 | Adults with obesity or overweight who did not have type 2 diabetes |
| SCALE Obesity and Prediabetes | Liraglutide 3.0 mg daily | 7.4% | 3% | 56 | Adults with type 2 diabetes who also had obesity or overweight |
| ATTAIN-1 | Foundayo 17.2 mg daily | 11.1% | 2.1% | 72 | Adults with obesity or overweight, without diabetes |
| ATTAIN-2 | Foundayo 17.2 mg daily | 9.6% | 2.5% | 72 | Adults with obesity or overweight who did not have type 2 diabetes |
| STEP 2 | Semaglutide 2.4 mg weekly | 9.6% | 3.4% | 68 | Adults with obesity or overweight who did not have type 2 diabetes |
Sources: STEP 1 (FDA label (DailyMed)), SURMOUNT-1 (FDA label (DailyMed)), SURMOUNT-2 (PubMed), SCALE Obesity and Prediabetes (FDA label (DailyMed)), ATTAIN-1 (FDA label (DailyMed)), STEP 2 (PubMed).
Source: FDA label (DailyMed).